Promega, G7018, ADCC Reporter Bioassay, V Variant

Eliminate the Uncertainty and Variability of Primary Cell Based ADCC Assays
Fc receptor-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) by which antibodies target diseased cells for elimination. The human FcyRIIIa gene displays a polymorphism in the position coding for amino acid residue 158. This translates to a higher affinity FcyRIIIa variant having a valine at amino acid 158 (V158) and a lower affinity FcyRIIIa variant carrying phenylalanine F158.
Classic methods used to measure ADCC use primary donor peripheral blood mononuclear cells (PBMCs) or purified natural killer (NK) cells that express Fc receptors on their cell surface. Killing of target cells is an endpoint of this pathway activation and is used in classic ADCC bioassays, which rely on donor peripheral blood mononuclear cells (PBMCs) or the natural killer (NK) cell subpopulation as effector cells isolated from blood donors.
These primary cell-based assays are highly variable in response, are tedious to prepare and can result in high background readings. The ADCC Reporter Bioassays overcome many of the limitations of traditional methods by eliminating the requirement for primary cell culture.